Bio-Techne Corporation (ETR:TE1)

Market Cap	9.74B +44.1%
Revenue (ttm)	1.06B -0.4%
Net Income	159.16M +147.8%
EPS	1.02 +152.2%
Shares Out	n/a
PE Ratio	61.22
Forward PE	36.36
Dividend	0.27 (0.44%)
Ex-Dividend Date	Aug 24, 2026

Volume	62
Open	62.10
Previous Close	62.18
Day's Range	61.82 - 62.38
52-Week Range	45.14 - 63.40
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1976
• Employees: 3,000
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: TE1

Financial Performance

In fiscal year 2026, Bio-Techne's revenue was $1.22 billion, a decrease of -0.38% compared to the previous year's $1.22 billion. Earnings were $181.84 million, an increase of 147.86%.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 14, 2026

Data Sources Report a data error